154 related articles for article (PubMed ID: 38740764)
1. Author Correction: Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.
Fleury H; Malaquin N; Tu V; Gilbert S; Martinez A; Olivier MA; Sauriol SA; Communal L; Leclerc-Desaulniers K; Carmona E; Provencher D; Mes-Masson AM; Rodier F
Nat Commun; 2024 May; 15(1):4011. PubMed ID: 38740764
[No Abstract] [Full Text] [Related]
2. Exploiting Cancer Synthetic Lethality in Cancer-Lessons Learnt from PARP Inhibitors.
Pettitt SJ; Ryan CJ; Lord CJ
Cancer Treat Res; 2023; 186():13-23. PubMed ID: 37978128
[TBL] [Abstract][Full Text] [Related]
3. Synthetic lethal genetic interactions between Rad54 and PARP-1 in mouse development and oncogenesis.
Tanori M; Casciati A; Berardinelli F; Leonardi S; Pasquali E; Antonelli F; Tanno B; Giardullo P; Pannicelli A; Babini G; De Stefano I; Sgura A; Mancuso M; Saran A; Pazzaglia S
Oncotarget; 2017 Nov; 8(60):100958-100974. PubMed ID: 29254138
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells.
Alotaibi M; Sharma K; Saleh T; Povirk LF; Hendrickson EA; Gewirtz DA
Radiat Res; 2016 Mar; 185(3):229-45. PubMed ID: 26934368
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
Yap TA; Sandhu SK; Carden CP; de Bono JS
CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
[TBL] [Abstract][Full Text] [Related]
6. Harnessing Synthetic Lethal Interactions for Personalized Medicine.
Shieh GS
J Pers Med; 2022 Jan; 12(1):. PubMed ID: 35055413
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer.
Wang Y; Zuo M; Jin H; Lai M; Luo J; Cheng Z
J Recept Signal Transduct Res; 2021 Jun; 41(3):304-311. PubMed ID: 32814472
[TBL] [Abstract][Full Text] [Related]
8. Targeting synthetic lethal paralogs in cancer.
Ryan CJ; Mehta I; Kebabci N; Adams DJ
Trends Cancer; 2023 May; 9(5):397-409. PubMed ID: 36890003
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibition as a prototype for synthetic lethal screens.
Liu X
Methods Mol Biol; 2013; 986():123-37. PubMed ID: 23436410
[TBL] [Abstract][Full Text] [Related]
10. Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.
Kawahara N; Ogawa K; Nagayasu M; Kimura M; Sasaki Y; Kobayashi H
Biomed Rep; 2017 Nov; 7(5):391-399. PubMed ID: 29109859
[TBL] [Abstract][Full Text] [Related]
11. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.
Chatterjee P; Choudhary GS; Sharma A; Singh K; Heston WD; Ciezki J; Klein EA; Almasan A
PLoS One; 2013; 8(4):e60408. PubMed ID: 23565244
[TBL] [Abstract][Full Text] [Related]
12. DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors.
Folly-Kossi H; Graves JD; Garan LAW; Lin FT; Lin WC
Cancer Res Commun; 2023 Oct; 3(10):2096-2112. PubMed ID: 37756561
[TBL] [Abstract][Full Text] [Related]
13. PARP inhibitors suppress tumours via centrosome error-induced senescence independent of DNA damage response.
Yue W; Li X; Zhan X; Wang L; Ma J; Bi M; Wang Q; Gu X; Xie B; Liu T; Guo H; Zhu X; Song C; Qiao J; Li M
EBioMedicine; 2024 May; 103():105129. PubMed ID: 38640836
[TBL] [Abstract][Full Text] [Related]
14. Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells.
Węsierska-Gądek J; Heinzl S
J Cancer Prev; 2014 Jun; 19(2):125-36. PubMed ID: 25337581
[TBL] [Abstract][Full Text] [Related]
15. DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity.
Malaquin N; Vancayseele A; Gilbert S; Antenor-Habazac L; Olivier MA; Ait Ali Brahem Z; Saad F; Delouya G; Rodier F
Cells; 2020 Jul; 9(7):. PubMed ID: 32630281
[TBL] [Abstract][Full Text] [Related]
16. Synthetic lethality guiding selection of drug combinations in ovarian cancer.
Heinzel A; Marhold M; Mayer P; Schwarz M; Tomasich E; Lukas A; Krainer M; Perco P
PLoS One; 2019; 14(1):e0210859. PubMed ID: 30682083
[TBL] [Abstract][Full Text] [Related]
17. XRCC8 mutation causes hypersensitivity to PARP inhibition without Homologous recombination repair deficiency.
Maeda J; Haskins JS; Kato TA
Mutat Res; 2023; 826():111815. PubMed ID: 36812659
[TBL] [Abstract][Full Text] [Related]
18. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
19. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.
Lord CJ; Tutt AN; Ashworth A
Annu Rev Med; 2015; 66():455-70. PubMed ID: 25341009
[TBL] [Abstract][Full Text] [Related]
20. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Chabanon RM; Morel D; Eychenne T; Colmet-Daage L; Bajrami I; Dorvault N; Garrido M; Meisenberg C; Lamb A; Ngo C; Hopkins SR; Roumeliotis TI; Jouny S; Hénon C; Kawai-Kawachi A; Astier C; Konde A; Del Nery E; Massard C; Pettitt SJ; Margueron R; Choudhary JS; Almouzni G; Soria JC; Deutsch E; Downs JA; Lord CJ; Postel-Vinay S
Cancer Res; 2021 Jun; 81(11):2888-2902. PubMed ID: 33888468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]